One challenge to HCV elimination through therapeutic intervention is reinfection. The aim of this analysis was to calculate the incidence of HCV reinfection among both HIV- Australia and New Zealand were assessed for HCV reinfection, confirmed by sequencing of the Core-E2 and/or NS5B regions. Reinfection incidence was calculated using persontime of observation. Exact Poisson regression analysis was used to assess factors associated with HCV reinfection. The cohort at risk for reinfection (n=120; 83% male; median age 36 years) was composed of HIV-positive men-who-have-sex-with-men (53%) and people who inject drugs (current 49%, ever 69%). Total follow-up time at risk was 135 person-years (median 1.08 years, range 0.17, 2.53). Ten cases of HCV reinfection were identified, for an incidence of 7.4 per 100 py (95% CI 4.0, 13.8). Reinfection incidence was significantly higher among participants who reported injection drug use at end of or post-treatment, irrespective of HIV status (15.5 per 100 py, 95% CI 7.8, 31.1). In adjusted analysis, factors associated with reinfection were older age (aIRR 5.3, 95% CI 1.15, 51.5, P=.042) and injection drug use at end of or post-treatment (aIRR 7.9, 95% CI 1.6, 77.2, P=.008). High reinfection incidence following treatment for recent HCV infection in individuals with ongoing risk behaviour emphasizes the need for post-treatment surveillance, harm reduction strategies and education in at-risk populations.
| INTRODUCTION
Highly effective, well-tolerated interferon-free direct-acting antivirals (DAA) have revolutionized hepatitis C virus (HCV) therapeutics, 1 with daily fixed-dose combination DAA regimens providing cure in >95% of individuals with chronic infection. 2, 3 The availability of DAA therapy has led to significant therapeutic optimism with the possibility of broad treatment uptake and subsequent HCV elimination. [4] [5] [6] [7] One challenge to HCV elimination through therapeutic intervention is reinfection.
There is concern that HCV reinfection may compromise the individual-and population-level benefits of HCV treatment in some populations with the risk of reinfection cited as a reason for not offering treatment to people who inject drugs (PWID). 8, 9 However, in general, the incidence of HCV reinfection in PWID treated for chronic HCV infection ranges between one and five per 100 py (summarized in Table   S1 ). Reinfection incidence following treatment in individuals with HIV/HCV co-infection is varied, with high incidence reported in some cohorts of HIV-positive men-who-have-sex-with-men (MSM).
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There is uncertainty around these reinfection estimates due to sample size, retrospective study designs, exclusion of recent PWID from trials, varied definitions for recent injection drug use and time at risk for reinfection, and the inability to accurately distinguish relapse from reinfection.
Mathematical modelling suggests that substantial reductions in HCV incidence and prevalence could be achieved by targeted DAA treatment scale-up among those at highest risk of ongoing transmission, including PWID and HIV-positive MSM with recently diagnosed HCV infection. 5, [13] [14] [15] Despite the high cost of DAA therapy, treating recent PWID and HIV-positive MSM with early liver disease appears to be cost-effective compared to delaying until cirrhosis, given the reduction in liver-related complications and additional benefit of averting secondary infections. 6, 7, 16 However, ongoing risk behaviours associated with HCV transmission may contribute to reinfection and compromise the population-level benefits of treatment as prevention. 5, 17, 18 Few studies have evaluated the incidence of HCV reinfection following treatment of recent HCV infection (summarized in Table S1 ), 11, 12, 19 a high-risk group for onward transmission and of importance as DAA treatment access expands to traditionally marginalized populations. The aim of this analysis was to calculate the incidence of HCV reinfection among individuals treated for recent HCV infection (estimated infection duration <18 months) and assess clinical and behavioural factors associated with reinfection. 
| MATERIALS AND METHODS

| Study participants
Individuals with recent HCV infection (infection duration
<18
| HCV RNA testing and sequencing
The presence of HCV RNA was assessed at all scheduled study vis- 
| Study definitions and outcomes
An end-of-treatment response (ETR) was defined as HCV RNA below the lower limit of detection, target not detected (LLoD, TND). HCV RNA recurrence was defined as quantifiable HCV RNA following ETR.
Post-treatment relapse was defined as the presence of quantifiable HCV RNA after an ETR, confirmed as homologous virus on sequencing of Core-E2 and/or NS5B regions as described. 23, 24 Confirmed reinfection was defined by the presence of quantifiable HCV RNA after an ETR with detection of an HCV strain that was distinct from the primary infecting strain (heterologous virus on sequencing). 
| Study oversight
| Statistical analysis
In the cohort at risk for reinfection (ETR without post-treatment re- 
| RESULTS
| Participant disposition
Between 2004 and 2015, 278 participants with recent HCV infection were enrolled in Australia and New Zealand with 196 participants included in the intention-to-treat population; 82 participants were enrolled into the untreated arms of ATAHC I and II ( Figure 1 ). An endof-treatment response (ETR) was documented in 77% (n=151). Six participants (4%) were lost to follow-up (LTFU) after ETR. Viral recurrence following ETR was seen in 35 (23%), confirmed by sequencing as relapse in 25 (17%) and reinfection in 10 (6%). Participants with relapse and LTFU after ETR were excluded from subsequent analysis.
The enrolment characteristics of the cohort at risk for reinfection (n=120; male 83%; median age 36 years, IQR 29-46) are shown in 
| HCV reinfection among participants treated for recent HCV infection
Ten cases of HCV reinfection were identified (eight confirmed, two possible), with persistent reinfection in five and spontaneous and was repeatedly negative subsequent to this.
Among all participants at risk for reinfection, reinfection incidence was 7.4 per 100 py (95% CI 4.0, 13.8; Tables 3 and S4) , for a projected cumulative reinfection incidence of 7.2% at 1 year and 14.5% at 2 years from end of treatment ( Figure S1 ). 
| Risk factors for HCV reinfection following treatment for recent infection
Factors associated with HCV reinfection were assessed using exact Poisson regression analysis ( Table S7 ). 
T A B L E 4 Factors associated with reinfection following treatment for recent HCV infection-exact Poisson regression analysis
HCV reinfection N=10
No reinfection
| DISCUSSION
This analysis assessed HCV reinfection incidence among individuals treated for recent HCV infection (duration of infection <18 months)
who achieved an end-of-treatment response. High levels of risk behaviour associated with HCV transmission were reported, including 38% reporting injection drug use at end of and/or post-treatment, predominantly methamphetamine. Ten cases of reinfection were identified for an overall reinfection incidence of 7.4 per 100 py. All cases occurred in men, the majority of whom were HIV-positive MSM (n=7) and reported injection drug use at end of and/or post-treatment (n=8). Two cases occurred in HIV-positive MSM who denied ever injecting drugs.
The incidence of reinfection following treatment for recent HCV infection reported in this analysis is consistent with previous studies among HIV-positive MSM and PWID (reinfection incidence:
9.6-15.2 per 100 py), [10] [11] [12] and expands upon the previous analysis limited to the predominantly HCV mono-infected ATAHC I cohort. 19 The higher incidence of HCV reinfection in this and other acute cohorts contrasts with the majority of published studies in individuals treated for chronic HCV infection (summarized in Table   S1 ). In a recent meta-analysis, Simmons et al. 
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Reinfection was associated with injection drug use following treatment and older age, the latter appearing to be related to older age and shorter time since injecting onset among PWID with reinfection.
Recent onset of injection drug use has been associated with HCV acquisition, though typically among young PWID. The treatment paradigm for individuals with HCV infection is evolving rapidly. 2, 3, 58, 60 The potential for broad access to highly effective, well-tolerated interferon-free DAA regimens has stimulated discussion around HCV treatment as prevention. HCV treatmentas-prevention strategies will be enhanced by early diagnosis and increased treatment uptake in recent HCV infection, to reduce transmission among at-risk populations. 5, 13 The significant risk for HCV reinfection following treatment in individuals with ongoing high-risk behaviour emphasizes the need for post-treatment surveillance, harm reduction strategies and education, 12,61 but must not be considered an impediment to treatment, if HCV elimination is to be achieved.
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